Evommune EVMN
NYSE EVMN
$6.91 -0.30 (-4.16%)
As of: Oct 2, 2026 · 12:15 PM EDT

Evommune (EVMN) Net Cash Flow (2024 - 2026)

Updated

Evommune (EVMN) reported Net Cash Flow of $11.51 million for Q2 2026, down 79.5% from $56.13 million a year earlier but up 170.9% from the prior quarter.

Analysis

Evommune (EVMN) Net Cash Flow (2024 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Evommune's Net Cash Flow came in at -$808,000; for FY2025, it was $29.02 million.

  • By year, Net Cash Flow came in at -$12.77 million in FY2024.
  • Five-year quarterly Net Cash Flow spans a low of -$33.82 million in Q3 2025 and a high of $56.13 million in Q2 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $4.25 million (Q1 2026), $17.25 million (Q4 2025) and -$33.82 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -1.27 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -2.82 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.53 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 757.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.62 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.95 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -4.43 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -722.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 652.90 Mn
10 Evommune 299.69 Mn -337.83 Mn - 11.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 11.51 Mn
Mar 31, 2026 4.25 Mn
Dec 31, 2025 17.25 Mn
Sep 30, 2025 -33.82 Mn
Jun 30, 2025 56.13 Mn
Mar 31, 2025 -10.55 Mn
Dec 31, 2024 -1.89 Mn
API Access

Evommune Net Cash Flow API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-cash-flow&ticker=EVMN&period=max&api_key=YOUR_API_KEY